Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T (CAR-T) cell-based therapies for the treatment of cancer. Its lead product candidates includes CYAD-101, an allogeneic CAR-T candidate that is in Phase 1 clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T therapy that is in Phase 1 clinical trial for the treatment of hematological malignancies and solid tumors. The company's preclinical candidates, include allogeneic CAR-T candidate for the treatment of solid tumors; CYAD-221, shRNA based allogeneic CAR-T candidate to treat B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting natural killer group 2D ligands (NKG2D) and an undisclosed membrane protein. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
IPO Year: 2015
Exchange: NASDAQ
Website: celyad.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/11/2022 | $20.00 → $11.00 | Overweight | Wells Fargo |
| 8/6/2021 | $17.00 → $15.00 | Buy | HC Wainwright & Co. |
SC 13D/A - Celyad Oncology SA (0001637890) (Subject)
SC 13D/A - Celyad Oncology SA (0001637890) (Subject)
SC 13D - Celyad Oncology SA (0001637890) (Subject)
SC 13G/A - Celyad Oncology SA (0001637890) (Subject)
Starting in 2023, Celyad Oncology is now entirely focused on its new business strategy with one clear objective: help to overcome the current limitations of CAR-T approaches. It plans to do this via (i) strengthening of its research focus centered around NKG2D, B7-H6 and shRNA platforms; (ii) maximizing the value of its IP estate and (iii) driving innovation through strategic collaborations. MONT-SAINT-GUIBERT, Belgium, March 23, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announces its financial results for the fiscal year 2022 e
MONT-SAINT-GUIBERT, Belgium, March 17, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announced that the Company will report full year 2022 financial and operating results on the evening of Thursday, March 23rd. Following the press release, the Company management will host a conference call on Friday, March 24th 2023 at 1 p.m. CET / 8 a.m. ET to discuss full year 2022 results and provide an update on the Company's recent changes and upcoming milestones. Participants may access the conference call by d
Enrollment ongoing in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory (r/r) multiple myeloma (MM)In July 2022, the U.S. Food and Drug Administration (FDA) lifted the clinical hold for the T-cell-inhibitory-molecule (TIM)-based allogeneic CAR T candidate CYAD-101 for metastatic colorectal cancer (mCRC)Company to increase strategic focus on collaborations related to broad intellectual property portfolioConference call and webcast scheduled for today, August 5th, at 2:00 p.m. CEST / 8:00 a.m. EDT MONT-SAINT-GUIBERT, Belgium, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD) (the "Com
MONT-SAINT-GUIBERT, Belgium, July 28, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company will report first half 2022 financial and operating results on the morning of Friday, August 5, 2022. Following the press release, Celyad Oncology management will host a conference call that day, Friday, August 5 at 2 p.m. CEST / 8 a.m. EDT to discuss first half 2022 results and provide an update on the Company's recent progress and upcoming milestones. Participants may access the conference call by dial
Highlights Phase 1 IMMUNICY-1 trial demonstrated encouraging data to date for CYAD-211 including a good tolerability profile and evidence of clinical activity in relapsed/refractory multiple myeloma (r/r MM) patientsInvestigation ongoing of findings in CYAD-101-002 Phase 1b trial following announcement of clinical hold by FDACash position of €30.0 million ($34.0 million) as of December 31, 2021Conference call and webcast scheduled for March 25 at 1:00 p.m. CET / 8:00 a.m. EDT MONT-SAINT-GUIBERT, Belgium, March 24, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD) (the "Company"), a clinical-stage biotechnology company focused on the discovery and development of chime
MONT-SAINT-GUIBERT, Belgium, March 17, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company will report full year 2021 financial and operating results on the evening of Thursday, March 24th. Following the press release, Celyad management will host a conference call on Friday, March 25 th at 1 p.m. CET / 8 a.m. ET to discuss full year 2021 results and provide an update on the Company's recent progress and upcoming milestones. Participants may access the conference call by dialing +1-412-317-606
Data continues to support the versatile potential of non-gene edited shRNA technology with updates from the CYAD-02 and CYAD-211 clinical programsManagement to host conference call today December 13th at 2:30 p.m. CET / 8:30 a.m. EST MONT-SAINT-GUIBERT, Belgium, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that data from the Phase 1 CYCLE-1 trial of CYAD-02 for the treatment of relapsed or refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) and the Phase 1
•Enrollment continues at dose level three in Phase 1 IMMUNICY-1 trial evaluating CYAD-211 in relapsed/refractory multiple myeloma (r/r MM); next clinical update expected by year-end 2021 •Phase 1b KEYNOTE-B79 trial set to evaluate CYAD-101 with KEYTRUDA® in metastatic colorectal cancer (mCRC) patients with microsatellite stable disease on-track to begin in the fourth quarter of 2021 •IND-enabling studies in progress for first-in-class shRNA-based allogeneic, IL-18-armored CAR T candidate CYAD-203 for solid tumors; submission of IND application anticipated in mid-2022 •CYCLE-1 trial evaluating autologous candidate CYAD-02 in r/r AML / MDS ongoing; preliminary data from dose level three cohor
MONT-SAINT-GUIBERT, Belgium, July 29, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company will report first half 2021 financial and operating results on the evening of Wednesday, August 4, 2021. Following the press release, Celyad management will host a conference call on Thursday, August 5 at 2 p.m. CEST / 8 a.m. EDT to discuss first half 2021 results and provide an update on the Company's recent progress and upcoming milestones. Participants may access the conference call by dialing +1 412
15F-12B - Celyad Oncology SA (0001637890) (Filer)
6-K - Celyad Oncology SA (0001637890) (Filer)
6-K - Celyad Oncology SA (0001637890) (Filer)
6-K - Celyad Oncology SA (0001637890) (Filer)
6-K - Celyad Oncology SA (0001637890) (Filer)
6-K - Celyad Oncology SA (0001637890) (Filer)
6-K - Celyad Oncology SA (0001637890) (Filer)
6-K - Celyad Oncology SA (0001637890) (Filer)
6-K - Celyad Oncology SA (0001637890) (Filer)
6-K - Celyad Oncology SA (0001637890) (Filer)
MONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), is a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies. The Company had previously announced on April 4th, 2023, that The Nasdaq Stock Market ("Nasdaq") notified the Company on March 31st, 2023 that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5450(b)(1)(A) for the Nasdaq Global Market, which requires that a listed company's stockholders' equity be at least $10.0 million. Further, on April 19th, 2023, as announced by the Company on April 24th, 2023, the Company received a n
MONT-SAINT-GUIBERT, Belgium, May 05, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announced that its Board of Directors has approved the voluntary delisting of its American Depositary Shares representing ordinary shares ("ADSs") from the Nasdaq Global Market, termination of its American Depositary Receipt ("ADR") facility and deregistration with the U.S. Securities and Exchange Commission (the "SEC") upon satisfaction of the requirements for deregistration. The Company will continue to be listed on Euronext Brussels. In connection w
Presentation of updated data on our multiplex shRNA platform, which allows targeting of up to four genes simultaneouslyPublication of results from the THINK trial, which provided proof-of-concept of our NKG2D-based CAR T-cell approach MONT-SAINT-GUIBERT, Belgium, May 05, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today reports its financial results for the first quarter of 2023 and provides an update on recent business developments. "Celyad Oncology is now fully committed to leveraging its expertise, know-how and intellectual p
MONT-SAINT-GUIBERT, Belgium, April 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received a letter (the "Bid Price Notice") on April 19th, 2023 from The Nasdaq Stock Market ("Nasdaq") informing the Company that the minimum closing bid price per share of its American Depositary Shares representing ordinary shares ("ADSs") was below $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Requirement"). The Bi
MONT-SAINT-GUIBERT, Belgium, April 04, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received a letter (the "Letter") on March 31, 2023 from The Nasdaq Stock Market ("Nasdaq") informing the Company that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5450(b)(1)(A) for the Nasdaq Global Market, which requires that a listed company's stockholders' equity be at least $10.0 million (the "Stockholders' Equity Requirement"). Based upon the reported stockholders' equity of approximately $4.6 million in the Compan
MONT-SAINT-GUIBERT, Belgium, March 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, is pleased to announce Georges Rawadi as its new Chief Executive Officer (CEO), effective as of March 23, 2023, with starting date April 17, 2023. Michel Lussier will continue to serve as Interim CEO until April 17 to facilitate transition. Georges Rawadi is a seasoned executive with over 20 years of experience in pharma/biotech, as research director, business developer, CEO and board member. He spent four years at Celyad Oncology (2014-2018) as Vice-Presi
Starting in 2023, Celyad Oncology is now entirely focused on its new business strategy with one clear objective: help to overcome the current limitations of CAR-T approaches. It plans to do this via (i) strengthening of its research focus centered around NKG2D, B7-H6 and shRNA platforms; (ii) maximizing the value of its IP estate and (iii) driving innovation through strategic collaborations. MONT-SAINT-GUIBERT, Belgium, March 23, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announces its financial results for the fiscal year 2022 e
MONT-SAINT-GUIBERT, Belgium, March 17, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announced that the Company will report full year 2022 financial and operating results on the evening of Thursday, March 23rd. Following the press release, the Company management will host a conference call on Friday, March 24th 2023 at 1 p.m. CET / 8 a.m. ET to discuss full year 2022 results and provide an update on the Company's recent changes and upcoming milestones. Participants may access the conference call by d
MONT-SAINT-GUIBERT, Belgium, March 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announced a non-cash impairment of its goodwill and intangible oncology assets. This impairment comes as a result of the Company's strategic shift in focus away from clinical development and the early stage nature of the implementation of the Celyad 2.0 strategy: shifting from an organization focused on clinical development to one prioritizing R&D discovery and the monetization of its intellectual property (IP) portfo
MONT-SAINT-GUIBERT, Belgium, March 01, 2023 (GLOBE NEWSWIRE) -- The following is a statement by Celyad Oncology: Dear Shareholder, 2022 has been a crossroad year for Celyad Oncology (the "Company"), with important changes and turning points. Whilst our clinical programs had clear potential, as we pursued clinical development over the years, we systematically discovered more effective ways of furthering our goal to impact cancer with CAR-T cell therapy. Also, Celyad transitioned from autologous to allogeneic approaches, which changed our company dynamic. We faced challenges stemming from insufficient clinical efficacy: our allogeneic program, CYAD-211, as evaluated in the IMMUNICY-1 trial
Wells Fargo reiterated coverage of Celyad Oncology with a rating of Overweight and set a new price target of $11.00 from $20.00 previously
HC Wainwright & Co. reiterated coverage of Celyad Oncology with a rating of Buy and set a new price target of $15.00 from $17.00 previously
HC Wainwright & Co. reiterated coverage of Celyad Oncology with a rating of Buy and set a new price target of $17.00 from $18.00 previously
JonesTrading downgraded Celyad Oncology from Buy to Hold
MONT-SAINT-GUIBERT, Belgium, March 24, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology ((Euronext &, NASDAQ:CYAD) (the "Company"), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, is pleased to announce Georges Rawadi as its new Chief Executive Officer (CEO), effective as of March 23, 2023, with starting date April 17, 2023. Michel Lussier will continue to serve as Interim CEO until April 17 to facilitate transition. Georges Rawadi is a seasoned executive with over 20 years of experience in pharma/biotech, as research director, business developer, CEO and board member. He spent four years at Celyad Oncology (2014-2018) as Vice-Presi
MONT-SAINT-GUIBERT, Belgium, June 24, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD) (the "Company"), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Board of Directors has named Hilde Windels as Chairwoman of the Board of Directors, effective immediately. Ms. Windels has been a member of the Board of Directors since May 2018. Ms. Windels serves on multiple boards in the life sciences industry and has been an executive in the sector from 1999 through 2021, serving primarily as Chief Financial Officer and, over the last five years, as Chief Execu
Enrollment continues in second dose cohort of Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory multiple myeloma (r/r MM); additional proof-of-concept data anticipated in second quarter 2021.Expansion segment of Phase 1 alloSHRINK trial evaluating allogeneic CYAD-101 administered concurrently with preconditioning chemotherapy for the treatment of advanced metastatic colorectal cancer (mCRC) ongoing; preliminary data expected in mid-2021.Phase 1b KEYNOTE-B79 trial evaluating CYAD-101 with KEYTRUDA® in patients with microsatellite stable mCRC expected to be initiated in first half of 2021. MONT-SAINT-GUIBERT, Belgiu
MONT-SAINT-GUIBERT, Belgium, April 19, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &, NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced the appointment of Dr. Charles Morris to the position of Chief Medical Officer. Dr. Morris will lead and provide strategic direction for all medical, regulatory and clinical development activities. "We are delighted to bring someone with Dr. Morris's vast expertise and experience on board during this pivotal time in the Company," said Filippo Petti, CEO of Celyad Oncology. "Dr. Morris has played an integral part in guiding mul
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that Marina Udier, Ph.D., has been appointed to its Board of Directors. “I am very pleased to welcome Marina to our Board of Directors,” stated Filippo Petti, CEO of Celyad Oncology. “As a highly regarded leader in the biopharmaceutical industry, we look forward to benefiting from Marina’s wealth of experience as we continue to advance key elements of our pipeline with the goal of developing innovative cell therapi
MONT-SAINT-GUIBERT, Belgium, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that Marina Udier, Ph.D., has been appointed to its Board of Directors. “I am very pleased to welcome Marina to our Board of Directors,” stated Filippo Petti, CEO of Celyad Oncology. “As a highly regarded leader in the biopharmaceutical industry, we look forward to benefiting from Marina’s wealth of experience as we continue to advance key elements of our pipeline with the goal of developing innovative cell therapies again